Piramal Pharma Solutions
3 articles with Piramal Pharma Solutions
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization
Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that it has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and supply of Plus’ Rhenium NanoLiposome (RNL™) intermediate drug product.
Piramal Pharma Solutions Invests ~$32 Million to Expand its Riverview Michigan Facility for Additional Capacity in Potent and Non-Potent API Development and Manufacturing
Piramal Pharma Limited’s Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced plans to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of Active Pharmaceutical Ingredients (APIs
Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish
Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), today announced that it is providing Bolt Biotherapeutics (Bolt) with the supply of both the BDC-1001 ISAC drug substance and the drug product for Bolt’s ongoing Phase 1/2 clinical study in cancer patients.